arrow
L

Laura E. Stevens

Dana-Farber Cancer Institute
H指数:13
被引数:1,169

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Histone H4 lysine 20 tri-methylation safeguards breast cancer lineage fidelity and unfolded protein response

组蛋白H4赖氨酸20三甲基化保护乳腺癌谱系保真度和未折叠蛋白反应

2026-08-220
OA
A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG)

一项关于在复发性高级别胶质瘤(rHGG)患者中,联合应用ipilimumab (IPI)和nivolumab (NIVO),并进行自体CD1c(BDCA-1)+/CD141(BDCA-3)+髓系树突状细胞(myDC)颅内给药的I期临床试验。

2024-09-010
PRE
Intratumoral (IT) administration of autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid dendritic cells (myDC) with the immunologic adjuvant AS01B plus ipilimumab (IPI) and IV nivolumab (NIVO) in patients with refractory advanced melanoma: A phase Ib clinical trial

在难治性晚期黑色素瘤患者中,通过瘤内(IT)途径给予自体CD1c(BDCA-1)+/CD141(BDCA-3)+髓样树突状细胞(myDC),联合免疫佐剂AS01B、ipilimumab(IPI)以及静脉注射nivolumab(NIVO):一项 Ib 期临床试验

2024-09-010
PRE
Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx- mediated resistance to HER2targeting therapies
2024-05-062
OAAI
KDM4C histone demethylase connects redox balance to chromatin remodeling via histone H3 tail clipping
2024-02-010
PRE
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer

TBCRC 039: 术前ruxolitinib联合或不联合紫杉醇治疗三阴性炎性乳腺癌的II期研究

2024-01-314
OAAI
Heterogeneity and transcriptional drivers of triple-negative breast cancer
2023-12-015
OAAI
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2022-11-2142
OAAI
EN1 Is a Transcriptional Dependency in Triple-Negative Breast Cancer Associated with Brain Metastasis
2019-08-1550
OAAI
T24 HRAS transformed NIH/3T3 mouse cells (GhrasT-NIH/3T3) in serial tumorigenic in vitro/in vivo passages give rise to increasingly aggressive tumorigenic cell lines T1-A and T2-A and metastatic cell lines T3-HA and T4-PA
2016-01-013
OAAI